---
title: "Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289805331.md"
description: "Context Therapeutics (NASDAQ:CNTX) reported interim Phase 1 data for CTIM-76, a CLDN6 x CD3 bispecific antibody, showing a 29% overall response rate in evaluable platinum-resistant ovarian cancer patients. The drug demonstrated a favorable safety profile with mostly Grade 1-2 adverse events and infrequent cytokine release syndrome. Pharmacokinetic data support future once-every-three-week dosing. Despite positive clinical signals, CNTX shares fell over 50% to $0.69."
datetime: "2026-06-15T15:10:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289805331.md)
  - [en](https://longbridge.com/en/news/289805331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289805331.md)
---

# Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

**Context Therapeutics Inc.** (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable safety profile in patients with advanced, late-line platinum-resistant ovarian cancer.

The data, based on a May 29, 2026, cutoff from the ongoing Phase 1 study, included 21 patients across ovarian, testicular, and endometrial cancers who received weekly doses ranging from 22.5 micrograms to 560 micrograms.

The biopharmaceutical company focused on advancing T cell-engaging bispecific antibodies for solid tumors.

**Read Also: Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients**

## Responses Observed At Active Dose Levels

Among patients treated at active dose levels of 140 micrograms to 280 micrograms, 13 patients received CTIM-76, and 10 were evaluable for efficacy after at least one post-baseline tumor assessment.

Seven platinum-resistant ovarian cancer patients were efficacy-evaluable at these dose levels. Two patients achieved confirmed partial responses, resulting in an overall response rate of 29%.

The disease control rate reached 57%, with four of seven patients achieving either stable disease or a partial response.

Context Therapeutics said three early-cohort patients who achieved stable disease or better maintained treatment benefit for at least six months.

The company noted that the 560-microgram dose exceeded target exposure levels with weekly dosing and was not advanced further in development.

## Safety Profile Supports Continued Development

According to the interim analysis, CTIM-76 demonstrated a safety profile consistent with the expected mechanism of action of T-cell engagers.

Most treatment-related adverse events occurred during the first or second dose and were predominantly Grade 1 or Grade 2 in severity.

The events were generally reversible with standard management.

Cytokine release syndrome events were infrequent among platinum-resistant ovarian cancer patients treated at active dose levels. One of nine patients experienced a Grade 1 event, with no higher-grade CRS reported.

## Pharmacokinetic Findings Suggest Dosing Flexibility

Pharmacokinetic analyses showed approximately dose-dependent increases in CTIM-76 exposure as dose levels increased.

The company said preliminary pharmacokinetic data support evaluating a dosing schedule of once every three weeks in future studies.

**CNTX Price Action:** Context Therapeutics shares were down 50.22% at $0.69 at the time of publication on Monday. The stock is near its 52-week low of $0.56, according to Benzinga Pro data.

_Photo via Shutterstock_

**Read Also: Trump Threatens 100% Tariffs On French Wine Unless Macron Drops Tax On Amazon, Apple, Meta And Others**

### Related Stocks

- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md)
- [AAPL.US](https://longbridge.com/en/quote/AAPL.US.md)
- [META.US](https://longbridge.com/en/quote/META.US.md)

## Related News & Research

- [CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients](https://longbridge.com/en/news/289805735.md)
- [Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook](https://longbridge.com/en/news/289813604.md)
- [Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals](https://longbridge.com/en/news/294389194.md)
- [CytomX Therapeutics (CTMX) Projected to Announce Quarterly Earnings on Thursday](https://longbridge.com/en/news/294339151.md)
- [Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/294341144.md)